BRVE starts Phase 3 for BHB-1893; cash funds into 2029
BRVE initiated Phase 3 trials for BHB-1893 in oHCM and nHCM. Cash reserves of $527.3 million post-IPO are expected to fund operations into 2029. Q2 2026 net loss widened to $18.6 million.
Story updates
08:14:39 PM UTC
SquawkNews
The company reported a net loss of $29.3M for the first half of 2026, driven by increased R&D and G&A expenses as it advances its lead HCM therapy through Phase 3 trials. Following a successful IPO raising $404.5M, cash resources are expected to fund operations into 2029, but significant risks rema…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.